This could be significant for researchers and flu-sufferers alike if the vaccine works similarly in humans. Currently, a new flu vaccine is developed annually based on predictions of what the most common flu strain will be in the next season.
“What we have done is design a strategy where you don’t have to think about matching the vaccine antigen to the virus at all,” Jeffery Taubenberger, MD, PhD, the study’s lead investigator said, according to HealthDay.
In the mice test, the vaccine was effective for at least six months and worked well in older mice.
“These initial findings are very positive, and suggest a promising and practical strategy for developing a vaccine with amazing, broad protection,” Dr. Taubenberger said.
More articles on the flu:
How to prepare for a major public health event: 5 tips from 4 Chicago hospitals
Vaccine-resistant viral mutations in the flu identified: 3 things to know
Researchers: 2 new bird flu strains don’t easily infect humans
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
